Clik here to view.
Prostate cancer reports from ASTRO: no. 1
Prostate cancer reports from the 50th annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), being held in Boston, are kindly provided by Eyad Abu-Isa, MD, a resident in...
View ArticleClik here to view.
Accuracy and relevance of clinical stage in diagnosis and prognosis of...
According to a new report from the University of California, San Francisco (to be published in Cancer this week), clinical staging errors may — at least in part — underlie the fact that the researchers...
View ArticleClik here to view.
What is the risk of NOT treating PSA-detected prostate cancer?
A new article in the May issue of Cancer Epidemiology, Biomarkers and Prevention appears to be a first attempt to project population-based probabilities of the occurrence of clinically significant...
View ArticleClik here to view.
Clinical and pathologic staging of localized prostate cancer: an update
A new review by Epstein, currently available on line in the Journal of Urology, provides a detailed analysis of the clinical significance of various factors in determining prognostic risk for newly...
View ArticleClik here to view.
Major new cancer clinical and genetic database to be built in Boston
According to an article published today in The Boston Globe, the Dana-Farber Cancer Center and Brigham and Women’s Hospital are working together to initiate development of a very large,...
View ArticleClik here to view.
Long-term outcomes after RP as first-line therapy for men with cT3 disease at...
We have no data from randomized trials on the relative effectiveness of surgery compared to radiation therapy in the treatment of men initially diagnosed with clinical stage T3NxM0 prostate cancer....
View ArticleClik here to view.
State of Victoria establishes regional prostate cancer registry (in Australia)
According to an article in BJU International, the State of Victoria, Australia, has initiated development of what appears to be a well-constructed, pilot, prostate cancer registry (PCR). Good for them!...
View ArticleClik here to view.
ASCO’s new CancerLinQ initiative
As we move near to the annual meeting of the American Society of Clinical Oncology (ASCO) — which will start at the end of May in Chicago — ASCO has been making a lot of noise about its prototype...
View ArticleClik here to view.
Genomic/genetic tests for risk for clinically significant prostate cancer
The precise ability of the various genetic/genomic tests now available to accurately analyze the risk for clinically significant prostate cancer based on biopsy tissue samples is an important factor...
View ArticleClik here to view.
Clinical and therapeutic histories of men who actually die of mCRPC
Despite all the prostate cancer research over the past 30 or so years, we still have limited information about the clinical and therapeutic history of prostate cancer in men who have progressive...
View ArticleClik here to view.
Help with finding out about clinical trials for prostate cancer treatment
Apparently the National Cancer Institute (NCI) has just re-funded the Fred Hutchinson Cancer Research Center in Seattle to the tune of $24 million to continue to operate what we see as an important,...
View ArticleClik here to view.
“Theranostics” in the management of prostate cancer
The word “theranostics” is a so-called “portmanteau” word made up from the words “therapeutics” and “diagnostics“. Thus, “theranostics” refers to the process of “diagnostic therapy” for individual...
View ArticleAstrology and the interpretation of data from clinical trials
Over the weekend, an interesting article on clinical trials appeared (somewhat unexpectedly) in the New York Times color supplement. The article, by Siddartha Mukherjee, MD, is entitled “A failure to...
View ArticleCTC levels as a surrogate endpoint for clinical trials in mCRPC
A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for...
View ArticleActive surveillance in Oz: a situation report
An interesting article published a couple of week’s ago in the Medical Journal of Australia reports on “real world issues” related to the implementation of active surveillance (AS) in Oz. Evans et al....
View ArticleWhole pelvic salvage radiation + short-term ADT improves oncologic outcomes
We didn’t expect to see data from the SPPORT trial for another 2 years, but the research team hit their recruitment goal early and have already been able to provide 5-year results.Alan Pollack, the...
View ArticleModern prostate cancer imaging: application of the right scan at the right time
A new “opinion” article in the Journal of Clinical Oncology this week has addressed the complex issue of how best to think about (a) how we are regulating use of and (b) how we are applying new forms...
View ArticleLAST CHANCE to participate in our current survey
By late yesterday nearly 600 men had completed our recent survey and most of them had expressed some degree of interest in participating in the quality of life trial we will be initiating soon. Again,...
View ArticleProstvac in the treatment of prostate cancer: an update
As many readers will remember, Prostvac is an active immunotherapeutic vaccine that — some years ago — had shown promising results in a randomized Phase II clinical trial. A multinational, three-arm,...
View ArticleNew prostate cancer imaging techniques and their use in clinical practice
An article by Vapiwala et al., just published in the Journal of Clinical Oncology, is a “must read” for patients who are trying to understand how new types of imaging technology are being applied in...
View Article
